Trials / Recruiting
RecruitingNCT06198517
Moxibustion for the Prevention of Hemorrhagic Cystitis After Allo-HSCT
Clinical Study of Moxibustion for the Prevention of Hemorrhagic Cystitis After Allogeneic Hematopoietic Stem Cell Transplantation
- Status
- Recruiting
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 266 (estimated)
- Sponsor
- Yi Zhang · Academic / Other
- Sex
- All
- Age
- 14 Years – 60 Years
- Healthy volunteers
- Not accepted
Summary
This study was a prospective, multicenter, randomized controlled clinical study planned to recruit 266 hematological patients with allogeneic hematopoietic stem cell transplantation (allo-HSCT), who were randomly divided into two groups according to gender, type of transplantation, and type of primary disease. The control group was treated conventionally, and the experimental group increased moxibustion of Zhongji, Guanyuan and Qihai for 30 min qd starting on the first day after HSCT was performed until the 14th day after transplantation. Urine routine tests were performed at the time of admission, +1d, and +14d, and urine BK virus, JC virus, and adenovirus were tested at four time points, namely, +1d, +14 days, onset of hematuria symptoms, and remission of HC, respectively; routine urine tests were performed once every 7 days for all patients within 100days. For patients with Hemorrhagic cystitis (HC), daily severity grading, pain scoring, cystitis symptom scoring, use of antispasmodic and analgesic medications, and major TCM evidence were recorded with the aim of evaluating the efficacy of moxibustion in the prevention of HC in this patient population.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | Moxibustion | The experimental group received moxibustion of Zhongji, Guanyuan, and Qihai for 30 min qd starting on the first day after HSCT was performed until the 14th day after transplantation, while treated conventionally. |
| OTHER | Symptomatic treatment | The control group received conventional symptomatic treatment. |
Timeline
- Start date
- 2024-03-21
- Primary completion
- 2026-06-30
- Completion
- 2026-09-30
- First posted
- 2024-01-10
- Last updated
- 2026-03-12
Locations
4 sites across 1 country: China
Source: ClinicalTrials.gov record NCT06198517. Inclusion in this directory is not an endorsement.